Healthcare, Pharma & Life Sciences

Seoul – October 13, 2026 -- Parkinson's patients taking the investigational drug solengepras gained an average of 36 more minutes of "good" movement time per day than those on their regular medication alone, and the drug will now be submitted to the U.S. Food and Drug Administration for approval.

ARISE trial results presented at the MDS International Congress

The data from the ARISE clinical trial were presented at the International Congress of Parkinson's Disease and Movement Disorders. Patients, who can have difficulty moving, also reported improvements in measures of daily living, according to the source.

Patient-reported outcomes were positive across all measured areas of daily living. Drooling and saliva control showed the most significant self-reported change, while improved daytime sleepiness was also recorded.

Beijing – October 13, 2026 -- T-MAXIMUM PHARMACEUTICAL has received FDA clearance to start a Phase 2 study of MT027, its B7-H3-targeted allogeneic CAR-T therapy, in patients with brain metastases from lung and breast cancer. It is the second Phase 2 program for the asset to clear the agency.

MT027 now has two FDA-cleared Phase 2 programs in intracranial solid tumors

The FDA previously cleared a Phase 2 study of MT027 in recurrent glioblastoma. The therapy holds Orphan Drug Designation and Fast Track Designation. The two programs give T-MAXIMUM a dual-indication portfolio covering both primary and metastatic intracranial solid tumors.

Sydney – October 13, 2026 -- The Safety Review Committee (SRC) for Racura Oncology's HARNESS-1 trial has cleared lead drug RC220 to escalate to 100 mg/m2, after finding no dose-limiting toxicities in either Cohort 1 patient. The Phase 1a/b study combines RC220 with osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Both Cohort 1 patients received RC220 at 50 mg/m2 by intravenous infusion alongside osimertinib at 80 mg daily. The second patient has received three RC220 doses, given 21 days apart, with no dose-limiting toxicities or treatment-related safety concerns.

Riyadh – October 12, 2026 -- Bristol Myers Squibb (BMS) employees in Saudi Arabia assembled and personalized more than 70 'Small Wins' toolkits for people living with schizophrenia, in partnership with the Saudi Schizophrenia Association ('Ehtiwaa'). The project was part of the 12th edition of BMS's annual Global Patient Week.

Ehtiwaa and BMS design a four-step kit to build daily motivation

The 'Small Wins: Everyday Activity & Motivation' toolkit guides patients through four steps: pick a card, try the activity, recognize the win, and add it to a jar. Each kit contains activity cards with optional suggestions such as listening to a favorite song, spending a few minutes outside or tidying one small space. A 'Small Wins Jar' with paper slips lets users record daily moments of joy. Each kit also carries a handwritten note from a BMS volunteer.

Taipei – October 12, 2026 -- China's National Medical Products Administration (NMPA) has approved CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, for adult patients with advanced prostate cancer, Foresee Pharmaceuticals (TPEx: 6576) said. Licensing partner Changchun GeneScience Pharmaceutical (GenSci) notified Foresee of the approval of the Marketing Authorization Application and will commercialize the product in China.

GenSci holds exclusive China rights across all CAMCEVI indications

The license covers all current and pipeline indications: advanced prostate cancer, central precocious puberty (CPP) and premenopausal breast cancer. Foresee Chairman and CEO Ben Chien said GenSci's China launch will "significantly contribute" to the growth of the company's global CAMCEVI franchise.

Seoul – October 12, 2026 -- CLASSYS Inc. (KOSDAQ: 214150) has created the post of Chief Commercial Officer and appointed former Bain & Company partner Jung-hee Bae to it, tasking her with a push toward a $1 billion revenue target ahead of 2030. Bae, who also becomes Vice President, will head the company's newly formed Go-to-Market (GTM) Center.

CLASSYS merges three sales and marketing divisions into one GTM Center

The appointment follows a restructuring that began after Jun-oh Yoon became CEO in July. The Marketing, Domestic Sales and Overseas Sales Divisions now sit under the GTM Center, which Bae will lead. The company said the aim is a stronger focus on markets and customers.

CLASSYS has spent 20 years entering international markets and launching products region by region. Since Yoon took office, it has been overhauling operations to standardize branding, products, positioning and global launches.

Linköping – October 12, 2026 -- UK digital pathology provider Diagnexia has signed an annual, renewable agreement with Sectra (STO: SECT B) covering up to 100,000 cases in the first year, enabling it to receive, send and report pathology cases digitally for NHS organisations.

The contract was signed in the second quarter of Sectra's 2026/2027 fiscal year. It uses Sectra's service for advanced share and collaborate workflows to connect Diagnexia with NHS bodies that need external specialist support.

Diagnexia reporting capacity becomes available through existing Sectra connections

Hospitals already connected to the Sectra Image Exchange Portal (Sectra IEP) can reach Diagnexia's reporting capacity through the same connection and workflows. Jane Rendall, Managing Director for Sectra UK and Ireland, said this requires no new integration, no separate supplier onboarding and no additional infrastructure.

Atlanta – October 12, 2026 -- Colquitt Regional Health System in Moultrie, Georgia, is the subject of an upcoming Public Television segment on how a South Georgia hospital used graduate medical education and expanded specialty services to build a regional training and care hub.

All Access crews filmed the Moultrie segment on September 21, 2026

The segment comes from "All Access hosted by Andy Garcia," an independent short-form documentary series produced for Public Television stations nationwide. It examines how localized investment affects patient outcomes and covers data diversity and local workforce development in rural health networks. Targeted facility expansions and intentional culture shifts are presented as the factors that attract top medical talent.

Kuala Lumpur – October 12, 2026 -- ASEAN Records has recognised Malaysia's ECO Bee Biotech Sdn Bhd for the first alcohol-free Halal Kelulut Golden Propolis extract made with Supercritical Fluid Extraction (SFE), a product developed with three Malaysian universities and honoured on innovation platforms in Malaysia, Canada and Croatia.

ECO Bee Biotech built its SFE process with three universities between 2017 and 2021

The company began exploring SFE green technology for Kelulut propolis in 2016. It then partnered with Universiti Teknologi Malaysia (UTM) in 2017, Monash University Malaysia in 2019 and Universiti Tunku Abdul Rahman (UTAR) in 2021. In 2018, the Malaysian Investment Development Authority (MIDA) granted the company Pioneer Status, which supported further development and commercialisation of the technology.

San Carlos – October 12, 2026 -- Fierce MedTech has named Noah Medical one of its 2023 "Fierce 15" medical technology companies, citing the growth of the Galaxy System, the company's first commercial platform for robotic navigated bronchoscopy.

Fierce MedTech credited Noah Medical's long-term plan to improve early diagnosis and treatment across multiple indications. The Galaxy System is a fully image-integrated platform aimed at minimally invasive early lung cancer diagnosis.

Galaxy System reports 100% tool-in-lesion accuracy in human trial

Noah Medical reports that the Galaxy System achieved 100% successful navigation to lesion, 100% diagnostic yield and 95% tool-in-lesion accuracy in a preclinical trial. In a human trial, it reported 100% tool-in-lesion accuracy and 90-95% diagnostic yield. The figures are company-reported, and the source gives no trial sizes.